Nu Skin Enterprises, Inc. (NYSE:NUS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, July 12th. The firm presently has a $70.00 price target on the stock. Zacks Investment Research‘s price target suggests a potential upside of 15.66% from the stock’s current price.
According to Zacks, “Nu Skin is a premier anti-aging company. The company’s anti-aging products feature the ageLOC line of products including ageLOC Tru Face Essence Ultra firming serum, the ageLOC TR90 weight management and body shaping system, ageLOC R2 nutritional supplement, and ageLOC Transformation daily skin care system. “
Several other equities analysts have also issued reports on the company. Bank of America Corporation upped their target price on Nu Skin Enterprises from $53.00 to $57.00 and gave the company an “underperform” rating in a report on Monday, July 10th. Pivotal Research reaffirmed a “buy” rating and issued a $80.00 target price (up from $65.00) on shares of Nu Skin Enterprises in a report on Thursday, June 22nd. Deutsche Bank AG upped their target price on Nu Skin Enterprises from $63.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, June 21st. ValuEngine raised Nu Skin Enterprises from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Finally, Sidoti lowered Nu Skin Enterprises from a “buy” rating to a “neutral” rating and set a $59.00 target price for the company. in a report on Wednesday, April 26th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $62.88.
Shares of Nu Skin Enterprises (NUS) remained flat at $60.52 on Wednesday. The company had a trading volume of 568,641 shares. The company’s 50 day moving average price is $62.87 and its 200-day moving average price is $56.44. Nu Skin Enterprises has a 12-month low of $46.35 and a 12-month high of $66.04. The stock has a market cap of $3.20 billion, a P/E ratio of 20.24 and a beta of 1.31.
Nu Skin Enterprises (NYSE:NUS) last issued its quarterly earnings data on Wednesday, August 2nd. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.69 by $0.08. The firm had revenue of $550.10 million during the quarter, compared to the consensus estimate of $548.09 million. Nu Skin Enterprises had a return on equity of 24.14% and a net margin of 7.53%. The company’s quarterly revenue was down 8.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.79 earnings per share. Equities analysts predict that Nu Skin Enterprises will post $3.23 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Upgrades Nu Skin Enterprises, Inc. (NYSE:NUS) to “Buy”” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/08/12/nu-skin-enterprises-inc-nysenus-upgraded-to-buy-by-zacks-investment-research-updated-updated-updated.html.
In other Nu Skin Enterprises news, President Ryan S. Napierski sold 8,000 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $65.00, for a total transaction of $520,000.00. Following the completion of the transaction, the president now directly owns 68,170 shares of the company’s stock, valued at $4,431,050. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel D Matthew Dorny sold 8,250 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $62.92, for a total value of $519,090.00. Following the completion of the transaction, the general counsel now directly owns 46,730 shares of the company’s stock, valued at $2,940,251.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,250 shares of company stock valued at $1,490,210. 5.20% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in Nu Skin Enterprises by 6.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,067,875 shares of the company’s stock worth $67,106,000 after buying an additional 64,767 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Nu Skin Enterprises during the second quarter worth approximately $255,000. Ramsey Quantitative Systems bought a new position in Nu Skin Enterprises during the second quarter worth approximately $354,000. Parametric Portfolio Associates LLC raised its position in Nu Skin Enterprises by 21.6% in the second quarter. Parametric Portfolio Associates LLC now owns 135,464 shares of the company’s stock worth $8,513,000 after buying an additional 24,054 shares during the last quarter. Finally, Harfst & Associates Inc. bought a new position in Nu Skin Enterprises during the second quarter worth approximately $373,000. 85.03% of the stock is owned by hedge funds and other institutional investors.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Nu Skin Enterprises Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nu Skin Enterprises Inc. and related companies.